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Abstract
Context: At present schistosomiasis is endemic in 78 countries, affecting more than 260 million people. Schistosomiasis haemato-
bia alone affects more than 112 millions.
Evidence Acquisition: We performed a computerized search of in PubMed database with keywords: Bladder Cancer Cost and Schis-
tosomiasis Mass Treatment.
Results: Bladder cancer is an important sequelae of this infection. In low-resource countries, where this disease is endemic, indi-
viduals inflicted with bladder cancer have very limited access to treatment and death is most probably certain.
Conclusions: Mass treatment with praziquantel is an easy, safe, and inexpensive treatment that could save the lives of thousands
and reduce the morbidity of millions.
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1. Context
Schistosomiasis, is an ancient scourge of mankind, de-
picted in papyri from Pharaonic Egypt and known from hu-
man remains over 2000 years from China. Human schisto-
somiasis is caused by six species: Schistosoma (S.) haemato-
bium, S. mansoni, S. japonicum, S. intercalatum, S. guineensis,
S. mekongi. A further species S. malayensis has been identi-
fied to infect humans in a limited focus in Malaysia (1).
Schistosomiasis was originally called bilharziasis in
homage to Theodor Bilharz, a young German pathol-
ogist, who first described the disease and its associa-
tion with Schistosoma worms, working at Cairo in Egypt.
Blood-dwelling Trematoda (phylum Platyhelminthes) of
the genus Schistosoma cause this chronic and debilitat-
ing disease (2). Schistosomes present a heteroxenic life
cycle, requiring as secondary host an invertebrate fresh-
water snail. Geographic distribution and maintenance
of human infection depend on the presence of a suitable
snail host. Adult worms are sexually distinct, a charac-
teristic that separates them from other flukes that are
hermaphrodites. Males present a ventral infolding from
the ventral sucker to the posterior end forming the gy-
necophoric canal, where females are kept during copula-
tion (copulatory groove). Schistosoma life cycle differs from
that of other flatworms also by infecting process of the
definitive host: the penetration of cercariae through the
skin. Of the Schistosoma species pathogenic to humans,
only Schistosomahaematobium causes urinary schistosomi-
asis (3). Snails of the genus Bulinus are the principle inter-
mediate hosts for S. haematobium. Animals may play a role
in S. haematobium infections as they may hybridize with
closely-related zoonotic Schistosoma spp. such as S. bovis
(4).
As of 1989 schistosomiasis was endemic in 76 countries
(5). Recent World Health Organization (2) report declared
that schistosomiasis is endemic in 78 countries (6, 7). The
estimated total number of people requiring treatment for
schistosomiasis in 2013 was 261 008 019, of whom 121 170
936 (46.4%) were school-aged children (5 – 14 years) (7).
S. haematobium is endemic in 53 countries in the Mid-
dle East and most of the African continent, including the
islands of Madagascar and Mauritius. Due to successful
eradication programs, the infection is no more of signifi-
cant public health significance in Egypt, Lebanon, Oman,
Syria, Tunisia, and Turkey, because transmission is low or
nonexistent. A disputed and ill-defined focus exists in India
and requires further confirmation (2). After more than 50
years, in which no more autochthonous cases of schistoso-
miasis were recorded in Europe, S. haematobium infection
has recently emerged in Corsica (8).
In this review, we discuss the basis for making benefi-
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cial therapeutic purposes in prevention, treatment, and re-
ducing the effects of schistosomiasis, such as bladder can-
cer mortality.
2. Evidence Acquisition
In this article, the cost of bladder cancer treatment and
the success of mass treatment for erradicanting schistoso-
miasis are reviewed. For the literature review, we have used
standard search strategies involving querying PubMed on-
line database, using key terms including “bladder cancer
Cost” and “schistosomiasis mass treatment”. No specific
key words have required as inclusion criteria. The refer-
ence lists of each article have been reviewed, in details, to
find additional articles. Articles found were reviewed inde-
pendently in full text.
3. Results
3.1. Schistosomiasis-Associated Bladder Cancer
Squamous cell carcinoma of the bladder (SCC) is a
malignant, poorly differentiated neoplasm. SCC is the
common form of bladder cancer in rural Africa, where
S. haematobium is prevalent (9, 10). By contrast, the ma-
jority of bladder cancer in developing countries and re-
gions not endemic for urogenital schistosomiasis is tran-
sitional cell carcinoma (TCC), which arises from the tran-
sitional epithelium lining of the bladder. The parasite
eggs trapped in the bladder wall release antigens and
other metabolites (presumably evolved to expedite eggs to
the urine, and hence to the external environment). The
phenomenon leads to hematuria and to chronic inflam-
mation, increasing the risk of SCC of the bladder. The
epidemiological association between SCC of the bladder
with schistosomiasis haematobia is based both on case
control studies and the correlation of bladder cancer in-
cidence with the prevalence of S. haematobium infection
within diverse geographic areas. The incidence of urogen-
ital schistosomiasis-associated SCC is estimated in 3 to 4
cases per 100 000, yearly (11). Schistosomiasis haematobia
is a chronic infection. The adult, egg-producing schisto-
somes live for many years, re-infections frequently occur,
and schistosomiasis-associated bladder SCC appears rela-
tively early, often by the mid-decades of life (TCC usually
presents in the later decades of life). In its recent mono-
graph, IARC (International Agency for Research on Can-
cer) confirmed that chronic infection with S. haematobium
causes the cancer of urinary bladder (12).
Our group has been working on the identification of
parasite derived compounds that might be implicated in
the carcinogenesis of S. haematobium. The majority of
these compounds are catechol estrogens. The genotoxic
effects of these estrogen metabolites might be attributed
to oxidation of catechol estrogens to quinones, followed
by redox cycling and formation of reactive oxygen species
that, in turn, react with DNA (13). Given the context of
the unarguable link between S. haematobium infection
and bladder cancer, the presence of putative carcinogenic
molecules in S. haematobiumeggs hopefully may have prac-
tical consequences for new approaches to disease control
(14, 15). The metabolism of estrogens and production of
depurinating estrogen–DNA adducts can be implicated in
a pathway underlying S. haematobium-promoted host cell
DNA damage, leading eventually to cell transformation.
The carcinogenic effect of this estrogen–DNA adduct medi-
ated pathway could explain the link between chronic schis-
tosomiasis haematobia and SCC of the bladder. We antici-
pate that these findings will contribute to understand how
schistosomiasis haematobia leads to SCC of the bladder
(13).
3.2. Treatment Cost of Bladder Cancer
Although the costs of medical care for bladder cancer
have been investigated extensively, patient time costs asso-
ciated with cancer care have rarely been estimated system-
atically. Yabroff and colleagues (16) identified 763,527 US
patients with cancer from 1995 to 2001. Net time cost esti-
mates for the initial phase of care were applied to national
estimates of numbers of new cancers in 2005 to obtain na-
tional time costs for the initial phase of care. According
to these authors in 2005, patient time costs for the initial
phase of care were 2.3 billion dollars (16).
In another example, the diagnosis and treatment of
bladder cancer represents a significant financial burden to
the population in the United States. Therapeutic advances
in bladder cancer care have come at a high cost to pay-
ers, providers, and patients. In this study, Noyes et al. (17)
describe the principles of cost-effectiveness evaluation in
healthcare and provide recommendations for a more eco-
nomical use of resources in bladder cancer care. Although
several studies have demonstrated that bladder cancer is
a common disease associated with substantial economic
burden for patients and society, the evidence supporting
the cost-effectiveness of many interventions in bladder
cancer care is limited and of insufficient quality. In addi-
tion, very little is known about the quality of life and the
preferred outcome measure for economic evaluations as-
sociated with bladder cancer states and treatments. More-
over, current clinical guidelines for bladder cancer care do
not incorporate economic factors while evaluating clinical
pathways (17).
In Canada, bladder cancer is the most costly malig-
nancy to treat per patient. Treatment options for bladder
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cancer are immediate cystectomy and conservative ther-
apy with intravesical Bacillus Calmette-Guerin (BCG). The
corresponding mean per-patient discounted lifetime costs
(in 2005 Canadian dollars) were $37,600 and $42,400, re-
spectively (18). In 2006, the annual cost of care for all
patients with muscle-invasive BC (MIBC) was $35.72M, 70%
more than the $21.03M for patients with non-MIBC. The ma-
jor cost drivers, regardless of disease stage, were diagnos-
tic/surveillance and complications, accounting for up to
43% and 37% of BC care costs, respectively. Co-morbidity-
adjusted incremental annual resource costs per patient
with MIBC were more than 4 times greater than those for
patients with non-MIBC, similar to those of OC controls (P
= 0.490-0.913), except for inpatient (P = 0.002) and hospice
(P < 0.001) costs, which were both statistically significantly
lower. Annual adjusted incremental Medicare reimburse-
ments totalled $36.3M for non-MIBC and $96.1 million for
MIBC (19).
In 2007, Konety and Allareddy (20) identified 6 577
American patients undergoing radical cystectomy for
bladder cancer from the Nationwide Inpatient Sample of
the Healthcare Cost and Utilization Project (1998 to 2002).
Of commonly performed urological cancer procedures,
radical cystectomy is associated with the highest morbid-
ity and mortality. According to these authors, the impact
of each individual type of complication or a combination
of them on various outcome measures, such as mortal-
ity, charges, and length of stay is unclear. They attempted
to quantify the impact of specific post-cystectomy compli-
cations and combinations thereof in terms of mortality,
charges, and length of stay. Although most patients under-
going cystectomy are older and have multiple comorbidi-
ties, the postoperative complications with the most signif-
icant impact were those directly related to surgery (pri-
mary complications). Secondary, complications (cardiac,
respiratory, vascular, etc) appear to have less of an impact
on most common outcome measures. The median total
charge was 41,905 dollars and median length of stay was
9 days (20).
The calculations of treatment costs are limited by the
fact that SCC may cause different costs than TCC and that
costs depend on the current exchange rate of a country’s
currency with the USD. However, figures allow an approx-
imate estimation of costs SCC would produce in industri-
alized countries if properly treated according to current
standards.
3.3. Mass Treatment of Schistosomiasis and Preventive
Chemotherapy
It has been previously shown that in patients treated
with praziquantel, pathological lesions of the urinary tract
disappear, as shown ultrasonographically (21). In these pa-
tients, the resolution of bladder lesions induced by urinary
schistosomiasis resulted in reversibility of urinary tract
obstructions 1 year after treatment with praziquantel (22-
24). Other chronic squeal like Symmers’ fibrosis has been
shown to be reversed by praziquantel (25).
We anticipate that the incidence of SCC in endemic
areas will decrease to that of non-endemic regions if pa-
tients with urinary schistosomiasis are regularly treated
from childhood on, in spite of constant re-exposure, as it
has been demonstrated (6, 7).
The literature provides us with several reports, in
which mass treatment with praziquantel with the purpose
of preventive chemotherapy of schistosomiasis is effective.
An intervention study was conducted in Khamir, north of
Sana’a Yemen, for control of urinary schistosomiasis, us-
ing chemotherapy. The prevalence of S. haematobium in-
fection 14 months post-intervention fell from 58.9% to 5.8%
and frequency of heavy infection from 40.0% to 18.9% (26).
Schistosomiasis and soil-transmitted helminthiasis (STH)
are among the neglected tropical diseases in Africa. A na-
tional control program for these diseases was initiated in
Uganda during March 2003. Annual treatment with praz-
iquantel and albendazole was given to school children in
endemic areas and adults in selected communities, where
local prevalence of S. mansoni in school children was high.
Two rounds of treatment significantly reduced the preva-
lence of S. mansoni infection in school children across 3
regions in the country from 33.4% - 49.3% to 9.7% - 29.6%,
and intensity of infection from 105.7 - 386.8 eggs per gram
of faeces (epg) to 11.6 - 84.1 epg. The proportion of chil-
dren with heavy S. mansoni infection was significantly re-
duced from 15% (95% CI 13.4%-16.8%) to 2.3% (95% CI 1.6%-
3.0%). In the current study, the authors showed that annual
anthelminthic treatment delivered to school children and
adults at high risk in Uganda could significantly reduce the
prevalence and intensity of infection for schistosomiasis
and STH, and both potentially and significantly reduce the
levels of environmental transmission of infection (27).
Likewise, in case of genital infection with S. haemato-
bium, it was shown that preventive chemotherapy could be
useful. Genital infection with S. haematobium is prevalent
in sub-Saharan Africa. Epidemiological studies have ob-
served that genital schistosomiasis is associated with an in-
creased odd of HIV infection among women. Ndeffo Mbah
et al. (28) estimated that, in S. haematobium high-risk com-
munities, targeted annual treatment of school-aged chil-
dren could reduce HIV prevalence by 20% (95% CI: 12%-31%)
in Angola, 16% (95% CI: 10%-32%) in Kenya, and 6% (95% CI:
3%-18%) in Zambia after the first 20 years of intervention
(28).
The latest success story in the literature was designed
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to assess the impact of a decade of biennial mass adminis-
tration of praziquantel on schistosomiasis in school-aged
children in Burkina Faso. In 2013, in a national assessment
based on 22 sentinel sites, 3 514 school children aged be-
tween 7 to11 years were checked for S. haematobium and S.
mansoni infection by the examination of urine and stool
samples, respectively. Ouedraogo et al. (29) analysed the
observed prevalence and intensity of infections and com-
pared these with the relevant results of earlier surveys in
Burkina Faso. Less than 1% of the children in 6 regions had
heavy S. haematobium infections. S. mansoni was only de-
tected in 2 regions. By mass use of preventive chemother-
apy, Burkina Faso may have eliminated schistosomiasis
as a public health problem in 8 regions and controlled
schistosome-related morbidity in other 3 regions (29).
On the other hand, the number of people treated for
schistosomiasis worldwide in 2013 was 39 485 376. This rep-
resents only 12.7% of the population requiring preventive
chemotherapy for schistosomiasis globally. Schistosomia-
sis treatments in 2013 were reported by 9 fewer countries
than in 2012. In 2013, 160 million praziquantel tablets were
delivered to countries in the African Region for the imple-
mentation of treatment. This would have been enough to
treat about 60 million people. The fact that little more
than 26 million people were treated in 2013 suggests that
the availability of praziquantel was not the only limiting
factor for schistosomiasis control in the region (7). Con-
sidering that there are at least 112 million people infected
with schistosomiasis haematobia (13, 30-32), and given that
3 to 4 in 100 000 individuals yearly develop bladder cancer
(see above), the incidence of SCC attributable to schisto-
somiasis expected would approximately amount to 5000
patients yearly with bladder cancer caused by S. haemato-
bium infection worldwide. The bladder cancer treatment
of these patients would cost at least 20 million USD per year
(see above).
In contrast, given that the individual cost per treat-
ment including logistic costs amounts to 0.32 USD and that
a biennial treatment is necessary to prevent serious mor-
bidity due to schistosomiasis, the annual cost per schis-
tosomiasis patient amounts to 0.16 USD (33). Mass ther-
apy which prevents SCC in schistosomiasis patients would
than cost 17.92 million USD per year and a chronic of-
ten incurable disease like SCC would be not only “treat-
ed” but safely prevented (34). If only school-aged chil-
dren (46.4%; 5 – 14 years) were targeted, the cost would
drop to 9.61 million USD. Affected populations would ben-
efit from other effects of praziquantel on other complica-
tions and sequeleae of schistosomiasis, including renal im-
pairment, increased transmission of HIV, HBV, HTLV and
other STDs sterility, complicated pregnancy, bleeding from
esophageal varices, to mention just a few (35-37).
4. Conclusions
Schistosomiasis is a neglected tropical disease, which
in early stages is a disease easy to treat and, thus, to elim-
inate schistosomiasis induced SCC. The problem to solve
is political rather than medical. More commitment is ur-
gently needed to tackle this disease. Leading policy makers
should be acquainted with these data. Are there simpler
and more cost-effective ways of combating cancer than
that to eliminate schistosomiasis induced SCC by preven-
tive praziquantel mass therapy? Preventing schistosomi-
asis is the best treatment and the least expensive way of
fighting bladder cancer in endemic areas.
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